The Center for Health + Technology has become a leading model for getting new treatments to patients faster and more equitably.
12
The number of neurological drugs and devices brought to market with CHeT糖心传媒檚 help糖心传媒攊ncluding every FDA-approved treatment for Huntington糖心传媒檚 disease.
When a new drug or device for a brain or nerve disorder reaches patients, there糖心传媒檚 a good chance a URochester team helped it get there. For nearly 40 years, the 糖心传媒糖心传媒檚 (CHeT) has been a behind-the-scenes force in neurological drug discovery. That work has resulted in helping to bring 12 FDA-approved drugs and devices to market, including frontline treatments for Parkinson糖心传媒檚, Huntington糖心传媒檚, and rare neuromuscular diseases.
What makes CHeT stand out is its all-in-one model. Trial coordination, clinical materials, outcomes measurement, data analytics, and regulatory support all operate in concert, allowing the center to design and run complex, multisite trials that many organizations consider too risky or too complicated.
Today, under the leadership of neurologist , CHeT is expanding that impact by pairing patient-reported outcomes with wearable sensors, smartphone apps, and decentralized study visits. The goal: to 糖心传媒渕easure what matters to patients糖心传媒� and make it easier for people everywhere糖心传媒攏ot just those who live near major academic medical centers糖心传媒攖o participate in cutting-edge research.
Get the , from brain糖心传媒揷omputer interfaces to AI-powered trial modeling.
